Curium has agreed to buy radiopharma peer Lantheus in an $8 billion deal, expanding scale in radioligand and imaging-focused oncology while reshaping the competitive landscape for radiopharmaceutical supply and commercialization. The transaction is structured at $102.5 per share for Lantheus, with the prospect of additional consideration for shareholders tied to performance targets. The announcement positions Curium to broaden its portfolio and strengthen its development and launch capabilities across nuclear medicine. In the same deal news flow, Sandoz also announced settlements related to US generic drug pricing antitrust litigation, reflecting parallel pressure on large healthcare companies across both innovation and generics portfolios. For the radiopharma market, the Lantheus acquisition would likely accelerate consolidation as companies compete to supply PSMA- and other modality-driven treatment regimens.